Nemaura Medical Inc. (NASDAQ:NMRD) Short Interest Update

Nemaura Medical Inc. (NASDAQ:NMRD) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 176,600 shares, an increase of 72.3% from the December 15th total of 102,500 shares. Currently, 2.0% of the shares of the stock are sold short. Based on an average daily volume of 43,200 shares, the days-to-cover ratio is presently 4.1 days.

A number of hedge funds and other institutional investors have recently bought and sold shares of NMRD. Charles Schwab Investment Management Inc. purchased a new stake in shares of Nemaura Medical during the second quarter worth about $134,000. Goldman Sachs Group Inc. purchased a new stake in Nemaura Medical in the second quarter valued at approximately $209,000. Bank of New York Mellon Corp purchased a new stake in Nemaura Medical in the second quarter valued at approximately $149,000. Bank of America Corp DE boosted its position in Nemaura Medical by 687.3% in the second quarter. Bank of America Corp DE now owns 11,990 shares of the company’s stock valued at $111,000 after buying an additional 10,467 shares during the last quarter. Finally, American International Group Inc. purchased a new stake in Nemaura Medical in the second quarter valued at approximately $38,000. 3.28% of the stock is owned by institutional investors.

Separately, ValuEngine lowered shares of Nemaura Medical from a “buy” rating to a “hold” rating in a report on Monday, December 21st.

NASDAQ NMRD opened at $4.57 on Thursday. The company has a quick ratio of 6.00, a current ratio of 6.14 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average of $4.05 and a two-hundred day moving average of $3.88. The firm has a market capitalization of $104.69 million, a price-to-earnings ratio of -22.85 and a beta of -0.33. Nemaura Medical has a 52 week low of $2.50 and a 52 week high of $16.50.

Nemaura Medical (NASDAQ:NMRD) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.07) EPS for the quarter.

Nemaura Medical Company Profile

Nemaura Medical Inc, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients.

See Also: Circuit Breakers

Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.